SNCA and dementia: These findings highlight the need for sensitive markers of alpha-synuclein pathology; while available biomarkers such as FP-CIT and MIBG are highly specific to DLB and MCI-LB, the sensitivity is lower than at the dementia stage (Roberts et al., 2021a, 2021b).